|Description||Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA receptor with potent antitumour activity.|
|Synonyms||(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid;hydrochloride Atrasentan hydrochloride Atrasentan HCl 195733-43-8 Atrasentan (hydrochloride) UNII-E4G31X93ZA Abbott 147627 Atrasentan hydr|
|Solubility||Soluble in DMSO|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -25℃ for long term (months to years).|
|Shelf Life||2 years|
|Quantity||Data not available, please inquire.|
|Boiling Point||659.4ºC at 760mmHg|
Endothelin 1 swine, human
Endothelin 1 (swine, human), a vasoconstrictor increased in plasma and explants of patients with uterine leiomyomas, is a synthetic peptide with the sequence of...
RO462005 is an endothelin receptor selective agonist.
atrasentan hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective anta...
Enrasentan, an indene derivative, has been found to be an endothelin receptor antagonist that was once studied in reperfusion injury and heart failure therapy.
Macitentan n-butyl analogue
Macitentan n-butyl analogue is a derivative of Macitentan, which is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle.
T-0201 has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonar...
BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.
FR 139317 is a selective Endothelin A receptor antagonist originated by Fujisawa. (Ki values are 1 nM and 7.3 μM at ETA and ETB subtypes respectively). No devel...
Sitaxentan sodium inhibits ET-1-induced stimulation of phosphoinositide turnover with a Ki of 0.69 nM and a pA2 of 8.0.
Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...
Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.
Edonentan, also known as BMS-207940, is a very potent and selective ETA endothelin receptor antagonist (Ki= 10 pM) that shows 80000-fold selective for ETA vs ET...
Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.
Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.
IRL-2500, an indol derivative, has been found to be an endothelin B receptor antagonist that was once studied in hypertension.
Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity.
BMS-187308, a sulfonamide derivative, has been found to be an endothelin-A (ETA) antagonist that was once studied about its activity against pressor effect in r...
Avosentan, also known as SPP301, R-639, and RO 67-0565, is a potent and selective endothelin receptor(ETA receptor) antagonist.
BMS 182874 Hydrochloride
This active molecular is a selective non-peptide Endothelin ETA receptor antagonist. It displays more than 1000-fold selectivity over ETB receptors (Ki of 48 nM...
Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.